Literature DB >> 34825187

Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells.

Shahinda S R Alsayed1, Amreena Suri2, Anders W Bailey2, Samuel Lane3, Eryn L Werry3,4, Chiang-Ching Huang5, Li-Fang Yu6, Michael Kassiou3, Simone Treiger Sredni2,7, Hendra Gunosewoyo1.   

Abstract

Paediatric glioblastomas are rapidly growing, devastating brain neoplasms with an invasive phenotype. Radiotherapy and chemotherapy, which are the current therapeutic adjuvant to surgical resection, are still associated with various toxicity profiles and only marginally improve the course of the disease and life expectancy. A considerable body of evidence supports the antitumour and apoptotic effects of certain cannabinoids, such as WIN55,212-2, against a wide spectrum of cancer cells, including gliomas. In fact, we previously highlighted the potent cytotoxic activity of the cannabinoid ligand 5 against glioblastoma KNS42 cells. Taken together, in this study, we designed, synthesised, and evaluated several indoles and indole bioisosteres for their antitumour activities. Compounds 8a, 8c, 8f, 12c, and 24d demonstrated significant inhibitory activities against the viability (IC50 = 2.34-9.06 μM) and proliferation (IC50 = 2.88-9.85 μM) of paediatric glioblastoma KNS42 cells. All five compounds further retained their antitumour activities against two atypical teratoid/rhabdoid tumour (AT/RT) cell lines. When tested against a medulloblastoma DAOY cell line, only 8c, 8f, 12c, and 24d maintained their viability inhibitory activities. The viability assay against non-neoplastic human fibroblast HFF1 cells suggested that compounds 8a, 8c, 8f, and 12c act selectively towards the panel of paediatric brain tumour cells. In contrast, compound 24d and WIN55,212-2 were highly toxic toward HFF1 cells. Due to their structural resemblance to known cannabimimetics, the most potent compounds were tested in cannabinoid 1 and 2 receptor (CB1R and CB2R) functional assays. Compounds 8a, 8c, and 12c failed to activate or antagonise both CB1R and CB2R, whereas compounds 8f and 24d antagonised CB1R and CB2R, respectively. We also performed a transcriptional analysis on KNS42 cells treated with our prototype compound 8a and highlighted a set of seven genes that were significantly downregulated. The expression levels of these genes were previously shown to be positively correlated with tumour growth and progression, indicating their implication in the antitumour activity of 8a. Overall, the drug-like and selective antitumour profiles of indole-2-carboxamides 8a, 8c, 8f, and 12c substantiate the versatility of the indole scaffold in cancer drug discovery. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34825187      PMCID: PMC8597418          DOI: 10.1039/d1md00065a

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  81 in total

1.  Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.

Authors:  Eric Stern; Giulio G Muccioli; Régis Millet; Jean-François Goossens; Amaury Farce; Philippe Chavatte; Jacques H Poupaert; Didier M Lambert; Patrick Depreux; Jean-Pierre Hénichart
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

2.  Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.

Authors:  Claudia Mugnaini; Antonella Brizzi; Alessia Ligresti; Marco Allarà; Stefania Lamponi; Federica Vacondio; Claudia Silva; Marco Mor; Vincenzo Di Marzo; Federico Corelli
Journal:  J Med Chem       Date:  2016-01-26       Impact factor: 7.446

3.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism.

Authors:  Stefano Fogli; Paola Nieri; Andrea Chicca; Barbara Adinolfi; Veronica Mariotti; Paola Iacopetti; Maria Cristina Breschi; Silvia Pellegrini
Journal:  FEBS Lett       Date:  2006-02-20       Impact factor: 4.124

5.  Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer.

Authors:  Tianyi Wang; Minwen Ha
Journal:  J Cell Biochem       Date:  2018-06-15       Impact factor: 4.429

6.  Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.

Authors:  Keiichi Kobayashi; Akiko Ohnishi; Jutabha Promsuk; Saki Shimizu; Yoshikatsu Kanai; Yoshiaki Shiokawa; Motoo Nagane
Journal:  Neurosurgery       Date:  2008-02       Impact factor: 4.654

7.  Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.

Authors:  C Sánchez; I Galve-Roperh; C Canova; P Brachet; M Guzmán
Journal:  FEBS Lett       Date:  1998-09-25       Impact factor: 4.124

Review 8.  Cannabinoids as therapeutic agents in cancer: current status and future implications.

Authors:  Bandana Chakravarti; Janani Ravi; Ramesh K Ganju
Journal:  Oncotarget       Date:  2014-08-15

9.  Pharmacomodulation of the Antimalarial Plasmodione: Synthesis of Biaryl- and N-Arylalkylamine Analogues, Antimalarial Activities and Physicochemical Properties.

Authors:  Karène Urgin; Mouhamad Jida; Katharina Ehrhardt; Tobias Müller; Michael Lanzer; Louis Maes; Mourad Elhabiri; Elisabeth Davioud-Charvet
Journal:  Molecules       Date:  2017-01-19       Impact factor: 4.411

10.  ArhGAP9, a novel MAP kinase docking protein, inhibits Erk and p38 activation through WW domain binding.

Authors:  Boon K Ang; Chun Y Lim; Sharon S Koh; Neelamegam Sivakumar; Shahrizan Taib; Kim B Lim; Sohail Ahmed; Guna Rajagopal; Siew H Ong
Journal:  J Mol Signal       Date:  2007-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.